From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents

被引：0
|
作者：
Caprio, Massimiliano [1 ,2 ]
Vitale, Cristiana [3 ]
Rosano, Giuseppe M. C. [3 ]
机构：
[1] IRCCS San Raffaele Pisana, Lab Cardiovasc Endocrinol, Rome, Italy
[2] San Raffaele Roma Open Univ, Dept Human Sci & Promot Qual Life, Rome, Italy
[3] IRCCS San Raffaele, Dept Cardiovasc & Resp Sci, Rome, Italy
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2021年 / 7卷 / 02期
关键词：
ACUTE MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; INSULIN-GLUCOSE; MORTALITY; LIRAGLUTIDE; PREVALENCE; OUTCOMES; RISK;
D O I：
10.1093/ehjcvp/pvaa019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：83 / 85
页数：3
相关论文
共 50 条
  • [31] Is it possible to reduce cardiovascular risk with glucose-lowering approaches?
    Gerstein, Hertzel C.
    NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (05) : 270 - 275
  • [32] Cardiovascular outcome trials of glucose-lowering medications: an update
    Home, Philip
    DIABETOLOGIA, 2019, 62 (03) : 357 - 369
  • [33] ANALYSIS OF CARDIOVASCULAR SAFETY OF NOVEL GLUCOSE-LOWERING MEDICATIONS
    Mkrtumyan, A. M.
    Markova, T. N.
    Mishchenko, N. K.
    KARDIOLOGIYA, 2019, 59 (07) : 76 - 83
  • [34] Cardiovascular outcome trials of glucose-lowering medications: an update
    Philip Home
    Diabetologia, 2019, 62 : 357 - 369
  • [35] Is it possible to reduce cardiovascular risk with glucose-lowering approaches?
    Hertzel C. Gerstein
    Nature Reviews Endocrinology, 2009, 5 : 270 - 275
  • [36] Potential of glucose-lowering drugs to reduce cardiovascular events
    Stuart W. Zarich
    Current Diabetes Reports, 2009, 9 : 87 - 94
  • [37] The cardiovascular phenotype: impact on choice of glucose-lowering therapy
    Kalra, Sanjay
    Gupta, Yashdeep
    Kishor, Kamal
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2016, 66 (04) : 480 - 482
  • [38] Sarcopenia with glucose-lowering drugs
    Reactions Weekly, 2021, 1875 (1) : 12 - 12
  • [39] Comparison of glucose-lowering drugs
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (09): : 736 - 736
  • [40] SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Preda, Alberto
    Montecucco, Fabrizio
    Carbone, Federico
    Camici, Giovanni G.
    Luscher, Thomas F.
    Kraler, Simon
    Liberale, Luca
    CARDIOVASCULAR RESEARCH, 2024, 120 (05) : 443 - 460
12345